NewLake Capital Partners, Inc. (NLCP) Earnings Call Transcript
November 5, 2026
Earnings Call Speaker Segments
Thanks, operator, and good morning to all of you. I'd like to welcome everyone to the conference call covering NewLake Capital Partners' financial results for the third quarter of 2026. With me on today's call are Gordon DuGan, our Chairman; Anthony Coniglio, our President and Chief Executive Officer; and Lisa Meyer, our Chief Financial Officer. Before we get started, I want to point out that some of what we say today could be viewed as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and that includes our guidance for full year 2026 AFFO. A range of risks and uncertainties could cause actual results to differ materially. For a more detailed discussion of those factors, please see the company's filings with the Securities and Exchange Commission, including our Form 10-Q for the quarter ended September 30th, 2026. We'll also be referencing non-GAAP financial measures during this call, including FFO and AFFO. You can find reconciliations to the most directly comparable GAAP measures in our earnings release; with that, I'd now like to hand the call over to our Chairman, Gordon DuGan.
Thanks, Valter, and good morning to everyone. NewLake continues to deliver solid financial outcomes for our investors. Third-quarter revenue and AFFO landed in line with expectations, since we keep completing new transactions successfully and are making real progress lowering risk throughout our portfolio. Through this year so far, we have gathered 99.7% of the rent we are contractually owed, and our dividend remains comfortably covered, with an AFFO payout ratio of 88%. These results please us, particularly given the persistent volatility and distress affecting some parts of the cannabis sector. When tenants have encountered difficulty, our team has worked hard to craft solutions that limit interruptions to rent and protect cash flow for our shareholders. Thanks to those efforts, NewLake has delivered steady results, but a small slice of the portfolio still needs attention. Well into 2026, we've brought in new tenants or executed fresh leases at properties that had been leased to The Cannabist, PharmaCann, and Acreage. In the majority of cases, the incoming operators assumed the leases already in place, and rent kept flowing with no gap. Those results reflect both the strength of our real estate and how hard our team works to resolve tenant issues. On the regulatory side, the industry has reached a turning point. Earlier this year, state-licensed medical cannabis was rescheduled to Schedule III — a historic first step. We expect the DEA to wrap up its rulemaking that would reclassify all cannabis into Schedule III, and the federal shutdown of the hemp loophole is scheduled to begin in December. Together, those developments set the stage for a much sounder regulatory landscape for the industry, bringing relief from the 280E tax burden, improved cash flow for operators, and fairer conditions for licensed operators who compete with unregulated, intoxicating hemp products. A sturdier tenant base supports how durable our rent is and creates fresh chances for NewLake to put capital to work. Looking ahead, NewLake is positioned very well. In the quarter, the remaining amount owed under our credit facility was fully repaid, and as of now NewLake stands out—perhaps uniquely—among publicly traded REITs in carrying no debt on its balance sheet. An accessible credit line lets us finance near-term investments sitting in our pipeline, and with an 88% AFFO payout ratio, we retain the financial room to expand while still sustaining our dividend. I'll now pass things to Anthony.
Thanks, Gordon, and good morning, everyone. We posted a stable third quarter, with revenue and AFFO in line with the second quarter. As Gordon noted, we paid off our credit facility during the quarter, so our balance sheet is now unlevered. We also pushed the facility's maturity out to 2029 and cut its pricing by 100 basis points, which keeps low-cost capacity available to fund our pipeline. Meanwhile, we're continuing to make headway at properties leased to tenants that are in court-supervised restructurings or under financial strain, while adding new properties to the portfolio under long-term leases. Let me begin with The Cannabist. As we already covered, The Cannabist has been going through a court-supervised process up in Canada; four properties are leased by us to The Cannabist: a dispensary plus a cultivation facility located in Illinois, along with a dispensary and a cultivation facility located in Massachusetts. Down in Aurora, Illinois, a new operator is in the process of buying The Cannabist's operations; a lease agreement has been signed by us with that acquiror, as well as a lease termination agreement with The Cannabist, and the two of them become effective at the moment the acquisition closes, which remains subject to the usual regulatory approval. Up until closing, the security deposit The Cannabist put down for this property went toward September rent. Regarding our three remaining Cannabist locations, contractual rent continues to come in full, with payments made through November, and we hold roughly a month's worth of security deposits at those properties. Back in July, Vireo Growth announced a deal to buy certain Cannabist assets across five markets, Illinois and Massachusetts among them. We're working closely with The Cannabist and other parties to reduce the chance of rent interruptions at our properties, and once we have more concrete details to share, we'll pass along updates. On PharmaCann: since our prior call, Cresco Labs closed its purchase of PharmaCann's Pennsylvania dispensaries, including operations at our property, and Cresco now guarantees that lease. Regarding the remaining two PharmaCann dispensaries, we're collaborating with that company while it explores a possible handoff of those operations to a different operator, and every rent payment is up to date. Turning now to what we've been investing in: since the start of the third quarter, we've completed three dispensary purchases, each one leased on a long-term basis to C3 Industries, a tenant we already have. In the third quarter, we finalized a Kentucky acquisition that we talked about during our prior call. After the quarter closed, we completed deals in Michigan and Kentucky. Michigan is the first state where we've made an investment, and you've heard us express hesitation over the years about states with unlimited licenses, including Michigan. We've watched that market closely, and it has matured. Much of the price compression has already occurred, and the operating environment is more stable now, which gives us a stronger foundation for underwriting deals there. This property also benefits from being in an area with limited licenses and is run by C3, a tenant we know well and whose Michigan performance we've tracked for years. All three properties that are open for leasing remain on the market and are being actively marketed, and as we typically do, we'll make new lease announcements once agreements are executed. Turning to regulation, the wider rescheduling effort continues to move forward. The administrative law judge's stay expired today; on November 2nd, the DEA started issuing its first federal registrations to over 900 state-licensed medical cannabis dispensaries spanning seven states — a significant step toward implementing the federal government's Schedule III framework. While pinpointing exactly when full-plant rescheduling will occur is difficult, recent briefings and proceedings leave me more confident that cannabis will in fact be moved to Schedule III. Now on hemp — the federal reclassification of hemp becomes fully operative on December 11th, which will eliminate intoxicating hemp goods that have been rivaling cannabis products legal at the state level. Lawmakers moved that deadline from November 12th as part of the most recent continuing resolution, and there's been scant willingness among legislators to push it back again. Similar to Ohio, where a ban across the state took effect earlier this year, we expect this limitation to fuel sales gains across our tenant base. Tuesday's historic election outcomes may significantly affect the cannabis sector. As everyone observed, Massachusetts voters turned down Question 4, which would have undone adult-use sales in that state, and we take encouragement from the fact that this initial effort to roll back cannabis legalization did not succeed. For the first time in 32 years, Democrats will control Pennsylvania's State Senate, creating a genuine opening for adult-use reform in the Commonwealth during 2027. We are likewise encouraged that candidates favoring reform prevailed in Texas, Wisconsin, and Iowa. Across the country, Democrats now clearly hold the upper hand in Congress over the coming two years, with majorities in both the House and the Senate. That situation might give the cannabis sector a chance to advance legislation, though we have seen this movie before. For years, cannabis banking reform has drawn backing from both sides, and yet Congress, even with both parties holding majorities at different points, has failed to finish the job. Seven times the House has passed the SAFER Banking Act, and in 2023 the Senate Banking Committee gave it approval, but a floor vote in the Senate has never happened. What might be different now is how the incoming Senate is composed. Cannabis reform supporters are expected to fill committee chair roles, and compared with the outgoing class, the next Senate should include more senators friendly to reform; until we hear from that group, we won't form any expectation about legislation moving forward. Finally, uplisting deserves attention, as it comes up frequently on our quarterly calls and in discussions with investors. Following Trulieve's reorganization into a medical-only business and its June listing on the New York Stock Exchange, we explored options for uplisting the approximately 50% of our portfolio leased to medical-only operations. Because of the expense and the duration needed to carry out a structure like that, along with our belief that full rescheduling is going to occur, we decided it wasn't worthwhile to pursue right now. We see rescheduling as a powerful possible catalyst for uplisting, and NewLake still meets the New York Stock Exchange and Nasdaq listing requirements apart from the exchanges' restrictions on cannabis-related businesses, and we plan to be well-positioned to move forward once the regulatory environment allows it. With that, I'll hand the call over to Lisa to go through our financial results in more detail.
Thanks, Anthony, and good morning. For Q3 2026, total revenue came in at $12 million versus $12.6 million a year earlier. Net income attributable to common stockholders was $4.2 million, equal to $0.20 per diluted share. FFO totaled $10 million, or $0.47 per diluted share, while AFFO came to $10.3 million, or $0.49 per diluted share. Across the nine months ended September 30th, 2026, revenue totaled $36.4 million, down from $38.7 million in the same stretch last year. Net income attributable to common stockholders reached $15.8 million, or $0.70 per diluted share. Funds from operations, or FFO, were $29.6 million, or $1.41 per diluted share, and adjusted funds from operations, or AFFO, were $30.7 million, or $1.46 per diluted share. The factors behind the year-over-year performance were largely the same for both the three- and nine-month periods ended September 30th, 2026. Revenue and AFFO took a hit mainly from three cultivation facilities sitting available for lease in Pennsylvania, Nevada, and Massachusetts, which lowered rental income and raised property carrying costs. That drag was partly offset by contractual annual rent escalators of roughly 2.6% across the portfolio, by rental income from the two Ohio dispensaries bought in 2025 — including rent tied to funded improvement allowances — and by rental income from the Kentucky dispensary purchased in August of 2026. As Anthony mentioned, during the quarter we signed a lease termination agreement with The Cannabist covering our Aurora property. Under that termination agreement, we recognized roughly $100,000 of rental income from The Cannabist security deposit in September, along with $1.9 million of accelerated amortization on an in-place lease intangible tied to The Cannabist lease at Aurora, which lowered net income for the period. Although net income fell by about $1.9 million, that accelerated amortization is a non-cash charge and sits outside both FFO and AFFO. On September 14th, 2026, our board of directors declared a quarterly cash dividend of $0.43 per share, which works out to $1.72 per share on an annualized basis. The dividend went out on October 15th, 2026, to stockholders of record as of September 30th, 2026. That reflects an AFFO payout ratio of 88%, still inside our 80% to 90% target range; it's worth noting that our portfolio's earnings power continues to fully support the dividend. Moving to the balance sheet, as of September 30th, 2026, gross real estate assets were $433.8 million, and cash and cash equivalents stood at $17.9 million. During the quarter we paid down $7.6 million outstanding on our revolving credit facility and finished the period with no debt outstanding; in August we amended our $90 million revolving credit facility, cutting our interest rate by 100 basis points and pushing the maturity date out to May of 2029. The facility stays available to fund future investments. Counting our third quarter dispensary acquisition plus the two properties acquired after quarter end, we had about $3.3 million in unfunded commitments for property improvements. Once those funds get put to work, they'll generate added contractual rent, which is embedded organic revenue growth. Also, in November our board of directors approved extending the stock repurchase program out to December 31st, 2028, and roughly $8.2 million is still available under it right now. On the whole, the quarter's results came in as expected. With no debt, a solid cash position, and credit capacity on hand, we feel we're well-positioned to go after attractive opportunities as the regulatory landscape for cannabis keeps evolving. Operator, please open the line for questions.
Thanks, and good morning, everybody. I appreciate the detail you provided on the The Cannabist and PharmaCann properties. Could you update us on Acreage and remind us how the guarantee from Canopy USA is structured there? Thanks.
Yes, good morning, Pablo. Where Acreage is concerned, we began a couple of years back with three properties leased to them. A business now guaranteed by GTI acquired one of those — a dispensary in Connecticut. Earlier this year, a transaction took place involving Acreage's Pennsylvania cultivation facility, and that transaction is now guaranteed by Holistic Industries; one property remains for us in Sterling, Massachusetts — a cultivation facility leased directly to Acreage. We hold a parent guarantee from the Acreage parent, along with a guarantee from Canopy USA, Canopy USA being the holding company that holds Canopy Growth's U.S. operations, including their common stock investment in TerrAscend, as well as Wana, Jetty, and then all of Acreage; regarding Acreage, what we know about Canopy USA is that, per the Canopy Growth disclosures from earlier this year, Canopy USA was in default of its credit agreement and actually had a stay of that until January of 2027; it keeps paying rent, it remains current, and we know the company is exploring strategic alternatives, and we are obviously looking at what they intend to do with our facility and what our options are should they decide that it is a facility they want to either monetize or move away from.
Thanks. About those vacant properties, my understanding is they're all for cultivation, correct? The two that came from AYR—Nevada and Pennsylvania—plus Rev Clinics in Massachusetts. If you could give us an update on those again, that would help. On the Massachusetts one, is it being marketed for cannabis or for other uses? Same question for the AYR ones. You'd imagine Pennsylvania would be the more interesting property now from a cannabis standpoint, but any color you can offer would help. Thanks.
Yes. Since the April rescheduling announcement, activity has picked up across every one of those properties, I'd say. In Massachusetts, I'd characterize it as somewhat of a pause among some of the folks who had recently been looking at that property, given the repeal vote that was on the ballot; now that voters resoundingly rejected it on Tuesday, we'll keep showing that property, and I believe interest in portions of it will only continue. I should note, though, Pablo, that we don't show properties exclusively for cultivation. We're always showing properties both to cannabis companies and to industrial companies. You're absolutely right that in Pennsylvania, with the State House flipping there and the Senate flipping, you will absolutely see interest, and we've seen continued interest in that Pennsylvania property; then in Nevada, there's strong interest in that property from non-cannabis companies as well as a couple of cannabis companies too. All told, we're seeing a decent flow of interest to all three of those properties. We've said before that we will only announce signed leases for available-for-sale properties. Announcing term sheets isn't something we want to do, because term sheets come and go, but leases are durable. Once we have a signed lease, we certainly will update our shareholders.
Thanks. I have just a few more questions. Perhaps one is for Lisa: when it comes to modeling Q4, you've clearly discussed the properties — the newly acquired ones — and what we've seen so far in the fourth quarter, but are there any moving parts, anything on the negative side we ought to keep in mind, particularly higher costs in Q4? Any color you could offer there? Thanks.
Costs should be more or less flat from one quarter to the next, I believe. I do expect you'll see a modest drop in income tied to the Aurora lease — there will certainly be a modest decline in income from that.
That's great. So Anthony, obviously I completely agree with all the positive developments we're hearing about at the state level, correct? You brought up Wisconsin, and there are additional states out there, and we'll see how things play out in Texas and naturally Pennsylvania. Looking closer in, could you discuss any states where you're noticing more activity, more incoming inquiries, folks exploring expansion, whether that's Ohio for cultivation or perhaps Virginia or Minnesota, if you could provide additional detail, focusing less on retail and more on cultivation, those inbound inquiries over the shorter term? Thanks.
We aren't receiving many inquiries regarding entirely new cultivation construction. In my view, Pablo, this sector remains reluctant to commit to major capital expenditure projects. If we did witness that, I believe it would be in a Texas or a Georgia, and at this point our pipeline simply doesn't show it. What we do see are folks who already operate cultivation sites wanting to turn those into cash to raise growth capital — capital that doesn't dilute — and that's occurring in cultivation operations along with retail locations. Then
That's the final one,
I realize we've discussed—apologies, let me return to this, sorry, Pablo,
Please continue.
I noticed I failed to address the particular question you raised. No — I wouldn't point to any single state as responsible for a disproportionate share of our portfolio. During the last quarter, we've come across opportunities spread throughout the country — I won't claim every state where cannabis is legal, but likely at least half of them. Among the very mature states, you saw us complete a deal in Michigan, which is a very mature state, and complete a deal in Kentucky, which is a very new state. Our pipeline doesn't yet show a pattern of opportunities clustering in any one particular state.
All right. This is the final question, and I realize we've discussed it before, yet with the helpful regulatory tailwinds and the possibility of additional capital becoming available to the industry—perhaps from the private side or elsewhere, or even from banks—I believe at the Benzinga conference recently, a number of banks offered some favorable remarks. Does that represent a new competitive source for you? Are people viewing sale-leaseback differently now, or is it simply business as usual and nothing out of the ordinary? Thanks.
No, Pablo, almost 8 years after they began, few companies face less competition, and we're among them. Outside of local landlords, it's difficult for us to identify anyone who has completed a new sale-leaseback in the cannabis industry during the last couple of years, but at a national scale, we really don't see anybody competing for sale-leasebacks. Regarding banks, my view is that they will first supply capital to a professionally managed, diversified commercial real estate portfolio—one like NewLake's—before moving into direct lending to cannabis operators. As this industry obtains greater access to capital markets, I think that works to our advantage. In fact, looking back, when we announced our $90 million credit facility 3 years ago—over 3 years ago—we were among the first to have a large-scale facility of that type in this industry. Again, I believe that's because we professionally manage this commercial real estate portfolio, which has diversification and professional underwriting of tenants, and in my opinion, a group that knows this industry is as good as anyone at underwriting it. I think banks will be slower both to enter the sector as normalization occurs and to move into direct lending to the industry.
Pablo, I’d just like to add one thing: since we’re a REIT that really doesn’t use much leverage, our cost of capital is far higher than it would be for a regular-way REIT — one with a standard market listing, the capacity to issue securities through an ATM to regular-way institutional investors, and access to debt markets in the same way as companies listed on the New York Stock Exchange and Nasdaq. Our capital structure has been very conservative, and that means our cost of capital is high. We expect that normalization will bring our cost of capital down substantially and let us be more competitive, grow our portfolio, and compete against other capital sources in this industry.
Yeah. Thanks — that's helpful context. Appreciate it.
Thanks to all of you for being with us today; we wish you a wonderful close to the year, and we're eager to speak with you once more in the first quarter. Thank you.
Thank you, everyone, for joining in — that brings today's teleconference to a close. You're welcome to hang up your lines now, and we hope the rest of your day is wonderful.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete NewLake Capital Partners, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to NewLake Capital Partners, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.